Background Diabetic kidney disease (DKD) progresses inexorably to kidney failure; whether initiating hemodialysis earlier than usual confers additional clinical benefit remains uncertain. Objective The aim of this study is to evaluate the effects of hemodialysis, compared with conventional medical care, on glycemic control, renal function, inflammatory markers, and treatment-related complications in adults with DKD. Methods We searched eight databases (Chinese Biomedical Database, Wanfang, CNKI, PubMed, EMBASE, ScienceDirect, Cochrane Library and VIP) and conference proceedings from January 2010 to 30 March 2025. Randomized controlled trials comparing hemodialysis plus standard therapy with standard therapy were eligible for inclusion in adult DKD patients. Two reviewers independently screened records extracted data and assessed risk of bias with the Cochrane Handbook 5.3 tool. Mean differences (MD) and 95% confidence intervals (CI) were pooled with random-effects models. Results Eight studies (645 participants) met the criteria. Compared with controls, hemodialysis significantly reduced parathyroid hormone (MD = − 37.30, 95% CI − 43.16 to − 31.43; I2 = 0%), tumour necrosis factor-α (MD = − 15.29, 95% CI − 25.05 to − 5.53; I2 = 89%), interleukin-4 (MD = − 20.42, 95% CI − 25.89 to − 14.94; I2 = 42%), and interleukin-8 (MD = − 13.56, 95% CI − 20.85 to − 6.27; I2 = 76%). Glycemic indices improved (fasting glucose MD = − 0.80, 95% CI − 1.59 to − 0.02; HbA₁c MD = − 0.63, 95% CI − 1.34 to 0.08). Serum creatinine (MD = − 1.03, 95% CI − 1.69 to − 0.36) and blood urea nitrogen (MD = − 0.94, 95% CI − 1.49 to − 0.39) also fell, despite high heterogeneity (I2 ≥ 99%). Four studies reported complications; pooled analysis showed no significant difference in overall adverse events (risk ratio = 0.91, 95% CI 0.62 to 1.34). Limitations Evidence is based on small, single-center studies with unclear allocation concealment, substantial heterogeneity for several outcomes, and no assessment of long-term clinical endpoints. Conclusion In adults with DKD, adjunctive hemodialysis improves biochemical surrogates of renal function, inflammation, and glycemic control without increasing short-term complications. Robust multicentre randomised trials powered for patient-important outcomes are warranted.

Efficacy and incidence of complications of hemodialysis in the treatment of diabetic nephropathy: a systematic review and meta-analysis

期刊论文
出版模式：

开放获取
发表日期：

2025年6月20日

查看全文

Xiaojing Liu,
Jingjing Zhou,
Conghui Liu,
Zhongxin Li

摘要

Background

Diabetic kidney disease (DKD) progresses inexorably to kidney failure; whether initiating hemodialysis earlier than usual confers additional clinical benefit remains uncertain.

Objective

The aim of this study is to evaluate the effects of hemodialysis, compared with conventional medical care, on glycemic control, renal function, inflammatory markers, and treatment-related complications in adults with DKD.

Methods

We searched eight databases (Chinese Biomedical Database, Wanfang, CNKI, PubMed, EMBASE, ScienceDirect, Cochrane Library and VIP) and conference proceedings from January 2010 to 30 March 2025. Randomized controlled trials comparing hemodialysis plus standard therapy with standard therapy were eligible for inclusion in adult DKD patients. Two reviewers independently screened records extracted data and assessed risk of bias with the Cochrane Handbook 5.3 tool. Mean differences (MD) and 95% confidence intervals (CI) were pooled with random-effects models.

Results

Eight studies (645 participants) met the criteria. Compared with controls, hemodialysis significantly reduced parathyroid hormone (MD = − 37.30, 95% CI − 43.16 to − 31.43; I² = 0%), tumour necrosis factor-α (MD = − 15.29, 95% CI − 25.05 to − 5.53; I² = 89%), interleukin-4 (MD = − 20.42, 95% CI − 25.89 to − 14.94; I² = 42%), and interleukin-8 (MD = − 13.56, 95% CI − 20.85 to − 6.27; I² = 76%). Glycemic indices improved (fasting glucose MD = − 0.80, 95% CI − 1.59 to − 0.02; HbA₁c MD = − 0.63, 95% CI − 1.34 to 0.08). Serum creatinine (MD = − 1.03, 95% CI − 1.69 to − 0.36) and blood urea nitrogen (MD = − 0.94, 95% CI − 1.49 to − 0.39) also fell, despite high heterogeneity (I² ≥ 99%). Four studies reported complications; pooled analysis showed no significant difference in overall adverse events (risk ratio = 0.91, 95% CI 0.62 to 1.34).

Limitations

Evidence is based on small, single-center studies with unclear allocation concealment, substantial heterogeneity for several outcomes, and no assessment of long-term clinical endpoints.

Conclusion

In adults with DKD, adjunctive hemodialysis improves biochemical surrogates of renal function, inflammation, and glycemic control without increasing short-term complications. Robust multicentre randomised trials powered for patient-important outcomes are warranted.